NEW YORK, Dec. 14 – Oxford GlycoSciences has extended for another year a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS said Friday.

Under the terms of the renewed agreement, OGS of Oxford, UK, will continue to use its proteomics technology to identify biomarkers in areas of interest to Pfizer. In exchange, Pfizer will provide additional research funding. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.